CYP2D6 rs5030658: Understanding Genetic Drug Metabolism
The rs5030658 variant is a specific genetic marker located within the CYP2D6 gene, which plays a critical role in how the body processes many common medications. Variations in this gene are associated with differences in enzyme activity, which can influence how individuals metabolize drugs ranging from antidepressants to pain relievers.
What each genotype means
Normal enzyme activity
This genotype is typically associated with normal CYP2D6 enzyme function, often referred to as an extensive metabolizer. Because this gene processes many common medications, your body likely metabolizes these drugs at a standard rate. Please discuss any medication dosing or potential side effects with your clinician or pharmacist.
This is the most common genotype globally, carried by the majority of individuals across most ancestral populations.
Likely reduced enzyme activity
This genotype suggests you may have reduced CYP2D6 enzyme activity compared to those with two functional copies of the gene. This can influence how your body processes certain medications, potentially leading to altered drug levels in your blood. Always consult your healthcare provider or pharmacist before starting new medications to ensure appropriate dosing.
This genotype is found at varying frequencies worldwide, with higher prevalence in populations where decreased-function alleles are more common.
Potential poor metabolizer status
This genotype is associated with significantly reduced or absent CYP2D6 enzyme activity, often classified as a poor metabolizer. This may result in slower processing of specific drugs, which can increase the risk of side effects or reduce the effectiveness of medications that require activation by this enzyme. Please inform your doctor or pharmacist of this genetic finding so they can adjust your treatment plan if necessary.
This genotype is less common globally, though its frequency varies significantly by ancestry, being more frequently observed in certain European and African populations.
What is rs5030658 and Where is it Located?
The rs5030658 variant is a single-nucleotide polymorphism (SNP) situated within the CYP2D6 gene. This gene is located on chromosome 22 and provides instructions for creating the cytochrome P450 2D6 enzyme. This enzyme is a member of the cytochrome P450 family, a group of proteins responsible for breaking down, or metabolizing, a vast array of substances in the body. Because the CYP2D6 gene is highly polymorphic, it contains many different variations, including SNPs like rs5030658, as well as larger structural changes like gene deletions or duplications. These variations can alter the structure or expression of the resulting enzyme, potentially changing its ability to process medications efficiently. Scientists track these specific locations in the genome to better understand why people respond differently to the same medical treatments.
The Role of the CYP2D6 Gene
The CYP2D6 enzyme is a workhorse of the liver, responsible for the metabolism of approximately 20% to 25% of all clinically used drugs. It acts by chemically modifying these substances, often through processes like hydroxylation, to make them easier for the body to eliminate or to activate them into their therapeutic forms. Because this enzyme is involved in processing such a wide variety of medications—including opioids, antidepressants, antipsychotics, and certain cardiovascular drugs—its functional status is a major focus of pharmacogenomics. When the CYP2D6 gene is altered, the enzyme may work too slowly, too quickly, or not at all. This variability can lead to differences in drug efficacy or the risk of adverse side effects, as the concentration of a drug in the bloodstream may be higher or lower than intended for a standard dose.
Research Associations and Evidence
Research into CYP2D6 is extensive, with many variants categorized into 'star alleles' that define an individual's metabolizer phenotype. These phenotypes range from poor metabolizers, who have little to no enzyme activity, to ultrarapid metabolizers, who process drugs much faster than average. The evidence linking specific CYP2D6 variants to drug response is generally considered strong, particularly for medications like codeine, where the enzyme is required to convert the drug into its active form, morphine. While rs5030658 is a recognized marker, it is often studied in the context of broader haplotypes or star alleles that dictate clinical function. It is important to note that while genetic associations are well-documented, clinical outcomes can also be influenced by other factors, such as drug-drug interactions, age, and liver health. Consequently, researchers emphasize that genotype alone does not provide a complete picture of an individual's drug response.
Population Frequency
The frequency of CYP2D6 variants varies significantly across different global populations. While the global frequency of specific variants like rs5030658 is often cited in the 1-3% range, the prevalence of various CYP2D6 alleles differs widely between European, Asian, and African ancestries. For example, certain no-function alleles are more common in European populations, while other decreased-function alleles are more prevalent in East Asian groups. These inter-ethnic differences mean that the distribution of metabolizer phenotypes is not uniform worldwide. Understanding these population-specific frequencies is a key component of global pharmacogenomic research, as it helps clinicians anticipate the likelihood of encountering specific metabolic profiles within different patient communities.
What You Can Do With This Information
Genetic information regarding CYP2D6 can be a valuable tool for personalized medicine, but it must be interpreted within a clinical context. If you have received results regarding your CYP2D6 status, it is essential to discuss these findings with your healthcare provider or a clinical pharmacist. They are trained to integrate genetic data with your current medication list, medical history, and other health factors to determine if a dosage adjustment or an alternative medication is appropriate. You should never change or stop taking a prescribed medication based on genetic test results without consulting a professional. Genetic testing is not a diagnostic tool for disease, but rather a guide to help clinicians optimize therapy. Always ensure that any genetic testing is performed in a certified laboratory and that the results are reviewed by a qualified medical professional.
How common is this variant?
The rs5030658 variant is found at a global frequency of approximately 1-3%, though the prevalence of various CYP2D6 alleles varies significantly across different ancestral populations.
Frequently asked questions
What does it mean to be a CYP2D6 poor metabolizer?
A poor metabolizer has little to no functional CYP2D6 enzyme activity. This means the body may process certain drugs very slowly, potentially leading to higher drug levels in the blood and an increased risk of side effects.
Can I use a home DNA test to guide my medication dosage?
While some home tests provide information on pharmacogenes like CYP2D6, you should never use this information to change your medication dosage on your own. Always share these results with your doctor or pharmacist, who can interpret them in the context of your specific health needs.
Does having a specific CYP2D6 genotype mean I will have side effects?
Not necessarily. A genotype indicates your potential for drug metabolism, but actual drug response is influenced by many factors, including other medications you are taking, your age, and your overall health. Genetic testing is just one piece of the puzzle.
Are all CYP2D6 variants the same?
No, the CYP2D6 gene is highly polymorphic, meaning there are many different types of variations. Some variants cause the enzyme to work faster, some cause it to work slower, and some stop the enzyme from working entirely.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030658?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
This variant is a key marker for the CYP2D6*10 allele, which results in reduced enzymatic activity and altered metabolism of various psychiatric and analgesic medications.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.
Defines the CYP2D6*17 allele (p.Thr107Ile), which exhibits reduced enzyme activity towards substrates like codeine and certain antidepressants.
Defines the CYP2D6*29 variant (p.Val338Met) conferring decreased metabolic capacity, primarily observed in populations of African descent.
Promoter variant defining the CYP2D6*41 allele, associated with reduced enzyme expression and decreased metabolic capacity for various drugs.
Defines the non-functional CYP2D6*41 splice defect associated with intermediate metabolizer phenotype affecting codeine, tamoxifen, and SSRI metabolism.